+44 (0)20 3910 4640 hello@symmetron.net
  • Twitter
  • Twitter
Symmetron
  • Services
  • Success stories
  • Therapeutic areas
  • Insights
  • The team
  • Careers
  • Contact
Select Page

Market access for immuno-oncology (I-O) therapies in the UK

by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology

The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing such treatments because of their complexity and high cost. As experts in...
  • November 2021
  • October 2021
  • August 2021
  • July 2021
  • Budget impact
  • Clinical trial
  • Cost-effectiveness analysis
  • Evidence generation
  • Evidence synthesis
  • Health economic modelling
  • Health outcomes
  • Healthcare
  • Market access
  • Medical affairs
  • NICE
  • Oncology
  • Services
  • Success stories
  • Therapeutic areas
  • Insights
  • The team
  • Careers
  • Contact
  • Privacy Policy
  • LinkedIn
  • Twitter
© 2021 Symmetron Limited